G-207 is under clinical development by Treovir and currently in Phase I for Ependymoma. According to GlobalData, Phase I drugs for Ependymoma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how G-207’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
G-207 overview
G-207 is under development for high-grade glioma in children, medulloblastoma, primitive neuroectodermal tumor, ependymoma, atypical teratoid/rhabdoid tumor and germ cell tumor, supratentorial brain tumor, gliosarcoma, glioblastoma multiforme, giant cell glioblastoma, midline diffuse glioma and anaplastic astrocytoma. The drug candidate is administered by intracerebral and intratumor routes. G207 is a modified herpes simplex type 1 virus (HSV) that has been genetically engineered to replicate aggressively in cancer cells to kill them while sparing normal cells. The drug candidate is based on HSV technology (now known as adeno-associated virus-like particles technology).
It was also under development for recurrent glioblastoma multiforme, gliosarcoma and anaplastic astrocytoma.
Treovir overview
Treovir is developing immunotherapeutic for the treatment of pediatric glioma. The company is headquartered in Wilmington, Delaware, the US.
For a complete picture of G-207’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
